• Skip to main content
  • Skip to primary sidebar
Imara
  • Real Impact Grants
  • Careers
  • Contact Us
  • Who We Are
    • Management
    • Board of Directors
    • Investors
  • Our Programs
    • IMR-687 & PDE9
    • Presentations & Publications
    • Clinical Trials
  • Patients & Families
    • Community Support
    • Resources
    • Imara Expanded Access Policy
  • Investors
    • Press Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Real Impact Grants
  • Careers
  • Contact Us

September 9, 2019

IMR-687: A Multimodal Mechanism of Action

IMR-687: A Multimodal Mechanism of Action

IMR-687 is a highly selective, potent small molecule inhibitor of PDE9 that has a multimodal MOA that acts primarily on red blood cells and has the potential to act on white blood cells, adhesion mediators and other cell types that are implicated in sickle cell disease.

Primary Sidebar

Contact Us

Sign Up for Imara Updates

TwitterLinkedIn

Imara, Inc.
116 Huntington Ave.
6th Floor
Boston, MA 02116
T: 617-206-2020
E: info@imaratx.com

Sign Up for Email Updates
Privacy Policy
Terms of Use
© 2020 Imara, Inc.

You are now leaving Imaratx.com

Links to sites outside of Imaratx.com are provided as a resource to the viewer. Imara is not responsible for and has no control over the content of linked sites.

No, I want to stay on Imaratx.com Yes, please proceed to the other site